).
Fluorouracil predominantly inhibits thymidylate synthetase, causing DNA damage, but RNA damage probably also contributes to the therapeutic effect in CRC. 8 Adjuvant systemic therapy with fluorouracil increases the cure rate of resected locally advanced colon cancer when combined with levamisole, leucovorin, and most recently with oxaliplatin and leucovorin. [9] [10] [11] The 5-fluouracil (5-FU) pro-drug capecitabine is also approved as part of curative therapy for rectal cancer in combination with radiation therapy, and as part of monotherapy or combined with oxaliplatin for colon cancer. 12, 13 In population-based registries, adherence to the NCCN guidelines for systemic adjuvant CRC treatment has been shown to correlate with improved survival for patients with high-risk Stage II and Stage III CRC.
patients with incurable metastatic CRC, angiogenesis inhibitors, epidermal growth factor inhibitors, a tyrosine kinase inhibitor, and a novel cytotoxic drug all can add to overall survival.
Angiogenesis Inhibitors
Formation of new blood vessels is a fundamental event in tumor growth and metastasis. The vascular endothelial growth factor (VEGF) family of proteins and receptors play a crucial role in angiogenesis. 15 Bevacizumab, a monoclonal antibody against VEGF, significantly improves overall survival when added to fluoropyrimidine-based chemotherapy with either oxaliplatin or irinotecan [16] [17] [18] and is approved for use in the first-line treatment of metastatic CRC. Bevacizumab has also shown a modest but significant improvement in overall survival (1.4 months) when continued beyond disease progression on first-line therapy and incorporated into the second-line regimen. 19 Ziv-aflibercept is a recombinant fusion protein that binds VEGF-A and VEGF-B. It is approved for second-line treatment of metastatic CRC in combination with FOLFIRI in patients who have previously experienced disease progression on an oxaliplatin-based regimen, based on a 1.4-month overall survival benefit. 20 Ramucirumab is a monoclonal antibody against VEGFR2. It is approved in combination with FOLFIRI for second-line treatment of metastatic CRC in patients who have previously progressed on FOLFOX plus bevacizumab, based on a 1.6-month overall survival benefit. 21 Because of concerns about toxicities and cost in the face of modest benefit, as well as unanswered questions about the effective sequencing of antiangiogenic agents, it is unclear whether ziv-aflibercept or ramucirumab will become commonly used therapies for metastatic CRC.
Epidermal Growth Factor Receptor Inhibition
Inhibition of the epidermal growth factor receptor (EGFR) pathway has also proven useful in the treatment of CRC. Only CRCs that are KRAS and NRAS wild type respond to the EGFR antibodies cetuximab and panitumumab. 22, 23 Among patients with metastatic CRC, the optimal sequencing of EGFR and antiangiogenic agents remains to be determined. In the Phase III U.S. Intergroup study of FOLFOX or FOLFIRI plus either bevacizumab or cetuximab among patients with KRAS wild type, untreated, metastatic CRC, median survival was the same (29 months) regardless of whether patients received bevacizumab or cetuximab. 24 However, a separate Phase III trial (FIRE-3) of first-line FOLFIRI plus cetuximab versus FOLFOX plus bevacizumab demonstrated a slight overall survival advantage for first-line FOLFIRI plus Emerging Systemic Therapies for Colorectal Cancer Veenstra, Krausscetuximab (28.7 vs. 25 months). 25 The controversial New EPOC study performed in the United Kingdom revealed that the addition of cetuximab to chemotherapy in CRC patients before and after a planned curative-intent resection of liver metastases resulted in worse overall survival, with a median survival of 14 months for the cetuximab plus chemotherapy arm and 20 months for the chemotherapy-only arm.
26
However, conclusions from this study have been called into question for many reasons, including concerns regarding variations in the quality of surgery for resection of liver metastases and inappropriate patient selection and randomization, 27 as well as concerns about the appropriateness of progression-free survival as the study's primary endpoint.
28
Among patients with Stage III CRC, the addition of EGFR antibody therapy to adjuvant FOLFOX chemotherapy did not provide a survival benefit 29 and cetuximab is not used in the adjuvant treatment of locally advanced CRC.
Oral Multitargeted Therapies
Regorafenib is an orally administered multi-kinase inhibitor that has been approved for treatment of metastatic CRC that has progressed through first-and second-line systemic therapies with 5-FU, oxaliplatin, irinotecan, a VEGF inhibitor, and, if appropriate, an EGFR antibody. The initial phase II study of regorafenib demonstrated a 74% disease control rate, with 4% partial response rate and 70% stable disease rate. However, the median number of days on treatment was only 49. 30 An international, placebo-controlled phase III study demonstrated an improved survival of 6.4 months for the regorafenib arm compared with 5 months for the placebo arm. 31 However, the complete and partial response rate was less than 1%. Among patients in the regorafenib arm, 41% had disease stabilization compared with 15% of patients in the placebo arm. In practice, regorafenib is not well tolerated by many patients and we have not seen widespread adoption of its use in palliative therapy of advanced CRC. It also seems unlikely that regorafenib will prove beneficial in curative-intent therapy for earlier stage disease. Trifluridine is a nucleic acid analog that, when given with the degradation inhibitor tipiracil hydrochloride, demonstrated antitumor activity in cell lines resistant to 5-FU.
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Trifluridine/tipiracil (TAS-102) was compared with placebo in patients with refractory metastatic CRC and improved median survival from 5.3 to 7.1 months. 33 Objective response rates were very low (1.6% in the trifluridine/tipiracil arm as compared with 0.4% in the placebo arm), but disease stabilization rates were significantly higher in the trifluridine/tipiracil arm (44%) compared with the placebo arm (16%). Similar to analyses of regorafenib, at the 4-month analysis, progression-free survival was 25% for patients in the trifluridine/tipiracil arm compared with 5% for patients in the placebo arm, indicating that the trifluridine/tipiracil offered a measure of disease control.
Novel Systemic Therapies for Colorectal Cancer
A selected listing of currently ongoing clinical trials of novel systemic therapies in the treatment of CRC is shown in ►Table 2 and described in more detail later. There are more than 10 genetic phenotypes that make up adenocarcinoma of the colon. In-depth genetic and proteomic characterization of 267 CRCs demonstrated that 15% had a hypermutated phenotype, while among the non-hypermutated tumors, mutations in APC (81%), TP53 (60%), and KRAS (43%) were the most common. 34 However, development of therapies directed at these common mutations has proven challenging, and most clinical trials in 2016 are directed at novel therapeutic targets. In lung cancer, identification of the critical role of EGFR mutations has led to the approval of erlotinib, a small oral tyrosine kinase inhibitor, as a more effective and less toxic systemic therapy for the treatment of metastatic lung cancer. 35 This example drives the search for finding and interrupting key signaling pathways in metastatic CRC.
34
Targeted Therapy
HER2/Neu-Directed Therapy
About 10% of colon tumors have amplifications of erb-2, suggesting that blockade of the HER2/neu pathway may prove of therapeutic benefit in some patients with metastatic CRC. While HER2/neu amplification is rare in CRC, the HER2/neu-amplified tumors tend to be more aggressive. 36 A phase II trial of dual HER2/neu-directed therapy with trastuzumab and lapatinib demonstrated an overall response rate of 35%, with a median time to progression of 5.5 months.
37

NTRK-Directed Therapy
Entrectinib is a potent small molecule inhibitor of the tyrosine kinases trkA (encoded by NTRK1), trkB (encoded by NTRK-2), trkC (encoded by NTRK-3), ALK, and ROS1. In preclinical models, treatment with entrectinib leads to apoptosis and downstream signaling effects on the tumor cells. 38 In the initial phase I study of various tumor types that contained amplification of the oncogenes, 10 responses were observed in the 11 patients treated at the recommended phase I dose, with durable responses lasting up to 16 months. 39 Loxo-101 is a TRK inhibitor that has demonstrated activity in preclinical models in tumors with TRK 1, 2, and 3 mutations. 40 A phase I study of this agent is ongoing (NCT02576431).
Exportin-1-Directed Therapy
Exportin-1 is a protein that mediates the nuclear export of over 200 cargo proteins, including many transcription factors important in the cancer phenotype. 41 Selinexor is an orally available, selective inhibitor of exportin-1 that has previously been tested in a phase I study. 42 Treatment with selinexor was associated with stable disease in 44% of CRC tumors with KRAS mutations. 43 It is currently being tested in a phase I trial with FOLFOX (NCT02384850).
Chemokine Inhibition
Macrophage migratory inhibitory factor (MIF) is a chemokine that is involved in many pathways of innate immunity. MIF overcomes the immunosuppressive effects of Emerging Systemic Therapies for Colorectal Cancer Veenstra, Krauss 181
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glucocorticoids, and can activate ERK1/ERK2 signaling.
44,45
Treatment with anti-MIF antibodies has demonstrated slowed tumor growth in a prostate cancer xenograft model.
46
Imalumab is a fully human monoclonal antibody specific for oxidized MIF. 47 Imalumab has been tested in a phase I study.
A maximum tolerated dose was not reached and nine patients (32%) had stable disease at the end of 2 months.
48
A phase II study of imalumab in CRC, in combination with either panitumumab or 5FU/leucovorin, is ongoing (NCT02448810).
Mitogen-Activated Protein Kinase Kinase (MAP2K1, Also Known as MEK)
The mitogen-activated protein kinase kinases MEK1 and MEK2 are of considerable interest in colon cancer. 49 The majority of the clinical trials currently recruiting patients are using MEK inhibition in combination with other systemic therapies (►Table 2). A phase I study of the MEK inhibitor binimetinib (MK162) in combination with FOLFOX chemotherapy has been conducted. In that study, 16 patients with metastatic colon cancer were treated. Ten patients had stable disease at 2 months, with five of those having stable disease for 5 months. 50 No dose-limiting toxicities were encountered. A phase I trial of binimetinib in combination with FOLRIRI has been registered (NCT02613650) and is planned at the University of Utah.
A phase I trial of the MEK inhibitor PD-0325901 in combination with crizotinib, being used as a MET inhibitor, the "MEK and MET Inhibition in Colorectal Cancer (MErCu-RIC1)," is ongoing at the University of Oxford (NCT02510001). A phase I/II study of the MEK inhibitor, selumetinib, in combination with the orally available EGFR inhibitor, afatanib, is planned for the Netherlands (NCT02450656). For this study, patients are required to have a KRAS (exon 2, 3 or 4) mutation and wild-type PIK3CA (defined as absence of mutations in exons 9 and 20). Preclinical results have demonstrated promising activity of inhibiting the MEK pathway with selumetinib and the Wnt pathway with cyclosporin A.
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Based on these results, a phase I expansion cohort of the MEK inhibitor selumetinib in combination with cyclosporine is being conducted at nine locations in North America (NCT02188264).
FGFR and MET Inhibition
Preclinical research studies have shown that BGJ398 selectively suppresses fibroblast growth factor receptor (FGFR) signaling and proliferation in cancer cells with FGFR dependency. Blockade of FGFR can also lead to decreased angiogenesis. 52 In addition, BGJ398 blocks bFGF-induced angiogenesis in endothelial cell lines. A phase I/II study is planned at Roswell Park, combining FGFR with FOLFOX (NCT02575508). The MET/hepatocyte growth factor pathway is important in thyroid cancer, lung cancer, colon cancer, and several other malignancies. 53 Constitutive activation of the MET oncogene pathway has been demonstrated in CRC, and has been associated with resistance to EGFR-based therapies.
54
Cabozantinib is a small molecule MET inhibitor that is approved for use in advanced medullary thyroid cancer. 55 Cabozantinib is being tested in metastatic colon cancer, alone and in combination with panitumumab (NCT02008383).
Angiogenesis and EGFR Inhibitors in Clinical Trials
Nintedanib is an oral tyrosine kinase inhibitor with activity against the VEGFR, FGFR, and PGFR pathways. 56 Nintedanib in combination with FOLFOX has been studied in a phase I/II clinical trial. 57 The study randomized 128 patients in a 2:1 randomization of FOLFOX plus nintedanib compared with FOLFOX plus bevacizumab. The FOLFOX plus nintedanib arm had 62% progression-free survival at 9 months, versus 70% in the FOLFOX plus bevacizumab arm. A phase I/II trial of capecitabine with nintedanib has been registered (NCT02393755), and will have the advantage of being an all-oral regimen.
Anlotinib is an orally available tyrosine kinase inhibitor, primarily of the VEGF pathway. It has been tested in a phase I study, resulting in stable disease in one patient. 38 A phase III trial of this agent has been registered (NCT02332499). PF-03446962 is a humanized monoclonal antibody directed at activin receptor kinase 1 (ALK-1). ALK-1 is involved in new blood vessel formation; therefore, inhibition of this pathway is being studied to inhibit tumor-induced angiogenesis. 58 PF-03446962 has been tested in patients with hepatocellular cancer with no objective responses, though some patients achieved stable disease. 59 It has been tested in refractory urothelial carcinoma with disappointing results.
60
Antibody-mediated blockade of the EGFR pathway is of clinical benefit in metastatic CRC. Sym004 is a mixture of two EGFR antibodies that target non-overlapping EGFR epitopes. The antibody combination induces rapid elimination of the EGFR receptor from the cell surface. 61 In a phase I trial of Sym004 in patients with refractory CRC, the combination had a clinical benefit in 17 of 39 (44%) patients with 13% achieving a partial response. 62 A phase II study of Sym004 versus a control arm has been registered (NCT02083653).
TRL-9 and Toll-Like Receptor 8
MGN1703, a subcutaneously administered TLR-9 agonist, is being studied as maintenance therapy for metastatic CRC (NCT02077868). A previous randomized phase II study in CRC patients demonstrated an improved progression-free survival for the patients treated with MGN1703, with a hazard ratio of 0.55.
63
Motolimod (VTX-2337) is a small-molecule agonist of toll-like receptor 8 that can directly activate dendritic cells, monocytes, and natural killer cells. 64 It is being tested for therapeutic efficacy alone or with a priming dose of cyclophosphamide (NCT02650635). Preliminarily, it was found to augment tumoricidal natural killer activity when administered to patients with head and neck cancer.
65
Agents without Molecularly Defined Targets
CPI-613 is an intravenous therapy that causes death of cancer cells but not of normal cells. 66 In a study of patients with hematologic malignancies, it resulted in a response in 4 out of 21 patients. 67 It has a dose-limiting toxicity of renal Emerging Systemic Therapies for Colorectal Cancer Veenstra, Krauss 183 failure. A phase I trial in combination with 5FU in CRC patients is ongoing. Genistein is a soy-derived phytoestrogen that has been investigated in cancer for its proapoptotic and antiproliferative properties. 68 Typical dietary intake of naturally occurring phytoestrogens ranges from 5 mg/day in Western Countries up to 200 mg/day in Asia. 69 Genistein has demonstrated synergy with 5FU in causing apoptosis of chemotherapy-resistant colon cancer cell lines. 70 It is being tested in a phase I study in combination with FOLFOX with or without bevacizumab.
Immunotherapy Approaches to Colorectal Cancer
Interest in immunotherapy as an approach to cancer treatment has grown substantially in recent years. In CRC, as in other solid tumors, treatments that maintain efficacy when standard chemotherapies have failed are desirable. Furthermore, treatments that selectively target cancer-dependent pathways and avoid the toxicities that result from chemotherapy's cytotoxic effect on healthy tissues stand to improve both objective responses to cancer treatment and patient tolerance of the treatment regimen. Immunotherapy approaches are designed to trigger the immune system to respond to tumor-specific antigens and attack and destroy tumor cells, ideally with minimal effect on normal tissues. Thus, many investigators and clinicians hope that immunotherapy will prove to be an effective strategy in the treatment of CRC.
Immune Checkpoint Inhibition and Modulation
Immune checkpoint modulation has been one of the most clinically promising immunotherapy treatment approaches to solid tumors to date. This approach to therapy depends on blocking those T cell receptors that inhibit T cell activity or upregulating those receptors that activate T cell activity (►Fig. 1). Inhibition of the PD-1/PD-L1 axis has produced exciting results in melanoma, 71 NSCLC, 72 and other solid tumors. Tumors with upregulation of the immune checkpoint proteins PD-1 and PD-L1 induce T cell anergy, thus allowing the cancer cells to survive. 73 Inhibition of these proteins using anti-PD-1 antibodies or anti-PD-L1 antibodies allows for T cell activation and has produced durable responses among patients with refractory solid tumors.
74-76
However, use of this therapy in CRC has so far shown promising results only among those patients with deficient mismatch repair (MMR). Approximately 15% of patients with CRC (including 4% of patients with advanced stage disease) have deficient MMR, either as a result of genetic inheritance of an inactive allele of one of the MMR genes (2.5% of patients) or sporadic inactivation of MMR genes (12.5% of patients). 73 Patients with deficient MMR accumulate a large number of mutations, particularly in regions of repetitive DNA sequences, resulting in microsatellite instability (MSI). It is hypothesized that these tumors incite a stronger T cell response because they carry more neoantigens and thus look more "foreign" to the native immune system. 77 Therefore, CRC patients with deficient DNA MMR may be particularly good candidates for checkpoint blockade therapy.
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A phase II study of PD-1 blockade with the anti-PD-1 antibody, pembrolizumab, in patients with stage IV CRC and non-CRC refractory to multiple previous lines of therapy reported an immune-mediated response rate of 40% in patients with MMR-deficient CRC, versus 0% in patients with MMR-proficient CRC. Immune-related progressionfree survival was 78% among patients with MMR-deficient CRC versus 11% among patients with MMR-proficient CRC. Neither median progression-free nor median overall survival rates were reached in the MMR-deficient cohort. Wholeexome sequencing revealed a mean of 1,782 somatic mutations in MMR-deficient tumors versus 73 in MMR-proficient tumors (p ¼ 0.007), and high loads of somatic mutations were associated with prolonged progression-free survival (p ¼ 0.02).
79 Though this was a small trial and included only 11 patients with MMR-deficient CRC, the results are promising and several additional studies of anti-PD-1 and anti-PD-L1 antibody treatments are ongoing. Keynote-164 (NCT02460198) is a large, phase II trial currently enrolling patients to assess the benefit of pembrolizumab for unresectable or metastatic MMR-deficient CRC that has been refractory to two or more previous lines of therapy. A selected listing of currently ongoing clinical trials of immune checkpoint inhibitors and modulators in the treatment of CRC is shown in ►Table 3, and described in more detail later. CTLA-4 represents another potential target for checkpoint inhibition in CRC. CTLA-4 is a T cell surface protein that, when bound by B7 protein on activated antigen presenting cells, inhibits T cell activation and induces T cell anergy. 80 Tremelimumab, a fully human monoclonal antibody against CTLA-4, was tested as single-agent therapy in a phase II trial of 47 patients with refractory metastatic CRC. The agent did not show significant activity in this study, although one patient had a partial response with a time from enrollment to disease progression of 14.5 months. 81 The MMR status of the patients was not reported in this study. Perhaps these agents will show activity in patients with MMR-deficient CRC, or in combination with other immunomodulatory Emerging Systemic Therapies for Colorectal Cancer Veenstra, Krauss 185
agents. There are currently several ongoing trials of the CTLA-4 inhibitors, tremelimumab and ipilimumab, alone or in combination with other immune checkpoint inhibitors, in the treatment of patients with advanced solid tumors including CRC. Like PD-1, LAG-3 is a negative regulator expressed during T cell activation. High-level, dual expression of LAG-3/PD-1 has been shown on tumor-infiltrating CD4þ and CD8þ cells in transplantable tumors in mice models. 82 Thus, inhibition of LAG-3 or combined LAG-3/PD-1 inhibition may promote antitumor immune responses. Clinical trials of an anti-LAG-3 antibody (BMS-986016), alone or in combination with the anti-PD-1 antibody, nivolumab, are currently ongoing in patients with solid tumors, including CRC.
Other potential targets for immune checkpoint modulation in CRC include members of the tumor necrosis factor receptor superfamily. These are costimulatory molecules that promote T cell activation. CD27 is one such molecule and plays a role in T cell survival, T cell activation, and the cytotoxic activity of natural killer cells. 83 Clinical trials of the CD27 agonist antibody varlilumab, alone or in combination with nivolumab, are ongoing. OX40 is another costimulatory molecule in this family. High levels of OX40 expression in tumor lymphocytes have been correlated with improved survival among CRC patients. 84 Studies of OX40 agonist antibodies (MEDI6469, MEDI6383, MOXR0916), alone or in combination with other immune checkpoint inhibitors, are ongoing. GITR is a surface receptor molecule involved in and BMS-663513, are currently being tested in phase I trials enrolling patients with CRC. These agents are being tested alone and also in combination with an anti-PD-1 antibody (nivolumab) and an EGFR antibody (cetuximab). One additional target for immune checkpoint modulation in CRC, KIR, is a receptor expressed on natural killer cells that binds HLA class I molecules on target cells, thus delivering an inhibitory signal that prevents natural kill-cell-mediated cytotoxicity.
87 An anti-KIR antibody, lirilumab, is currently being tested in combination with nivolumab in a phase I trial in patients with advanced solid tumors, including CRC. While promising, immune checkpoint inhibition and modulation does not yet play a role in the standard treatment of patients with CRC. It seems likely that inhibition of the PD-1/PD-L1 axis will become standard therapy for patients with metastatic, MMR-deficient (MSI-high) CRC, though additional prospective studies are needed to confirm the benefits seen in early studies in this patient cohort. Whether immune checkpoint inhibition or modulation will show clinical efficacy in patients with MMR-proficient CRC, as first-line therapy of metastatic disease, or in earlier stage disease, remains to be seen.
Adoptive Cell Therapy
Adoptive cell therapies using autologous T cells that have been genetically engineered to express high-affinity receptors for tumor-associated antigens have produced exciting responses in melanoma. [88] [89] [90] This treatment approach has also been tested in CRC patients. In a phase I clinical trial, three patients with metastatic CRC were treated with autologous T lymphocytes genetically engineered to express a murine T cell receptor against human carcinoembryonic antigen (CEA). All three patients had significant decreases in their serum CEA levels and one patient had objective regression of metastases in the lungs and liver. These responses were transient, however, with eventual disease progression. Furthermore, all three patients developed severe, transient inflammatory colitis leading to cessation of the trial.
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Clinical trials of chimeric antigen receptor (CAR)-modified T cells have led to dramatic and sustained responses in hematologic malignancies. 92, 93 Some of the first phase I clinical trials using CAR T cells were done in patients with metastatic CRC. The treatment was well tolerated, but no objective responses were observed. 94 A later study of second-generation CAR T cells targeting ERBB2 in a patient with metastatic CRC resulted in almost immediate development of respiratory distress, cytokine storm, and, unfortunately, the patient's death. 95 The cause of death was thought to be T cell reaction to the normal, low-level expression of ERBB2 in healthy lung tissue. This case and others highlight the potential for extreme toxicity with adoptive cell therapies, and subsequent research has focused on strategies to increase the safety of adoptive cell therapy.
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Attempts to successfully incorporate adoptive cell therapies in the treatment of solid tumors, including CRC, are ongoing. 97 A phase I study of cytotoxic T lymphocytes specific for the tumor-associated antigens NY-ESO-1, MA-GEA4, PRAME, survivin, and SSX (NCT02239861) and a separate phase I study of NY-ESO-1-specific cytotoxic T lymphocytes (NCT01967823) are currently enrolling patients with advanced solid tumors, including CRC. Two phase I/II studies of CAR T cells, one specific for VEGFR2 (NCT01218867) and one specific for EGFR, are enrolling metastatic CRC patients. The National Cancer Institute is currently recruiting patients with advanced solid and hematologic malignancies, including CRC, to a phase I study of tumor infiltrating lymphocytes, which are infused following a non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine (NCT01174121).
Vaccine Therapy
Cancer vaccines are designed to elicit an immune response against tumor-specific or tumor-associated antigens. Further research to better understand the genetic drivers of CRC may lead to novel targeted agents or combinations of targeted agents to inhibit multiple genes. Additionally, understanding how to drive the immune system in a more specific manner may increase the efficacy and reduce the toxicities of immunotherapy approaches to CRC, and hopefully provide benefits that extend to all CRC patients. Regimens that combine immune therapies or small moleculetargeted agents with conventional chemotherapies to target several different pathways, coupled with further research into the optimal sequencing of these therapies, may lead to sustained responses and improved outcomes. Systemic therapies for advanced CRC that improve response rates and allow for successful surgical resection of metastatic disease could potentially improve overall survival and even increase cure rates for a substantial number of patients.
